Key Takeaways
- • Apheon acquired a majority stake in Hager & Meisinger, a manufacturer of high-precision dental rotary instruments operating under the Meisinger and Jota brands.
- • Hager & Meisinger distributes its products across more than 100 countries, indicating an established global market presence in the dental instruments sector.
- • The transaction represents Apheon's entry into or expansion within the dental instruments and medical device market.
Summary
Apheon has acquired a majority stake in Hager & Meisinger, a dental instruments manufacturer with established global distribution capabilities. The company produces high-precision dental rotary instruments marketed under two recognized brands: Meisinger and Jota, which are sold in more than 100 countries worldwide.
The acquisition positions Apheon within the specialized dental instruments market, a niche sector serving dental professionals globally. Hager & Meisinger's multi-brand portfolio and international reach across more than 100 markets suggests a well-established operation with diversified geographic revenue streams. The majority stake acquisition indicates Apheon's strategic interest in consolidating control of the business and its operations.
The transaction details—including the acquisition price, the percentage stake acquired, financing structure, and expected closing timeline—were not disclosed in available reporting.
The acquisition positions Apheon within the specialized dental instruments market, a niche sector serving dental professionals globally. Hager & Meisinger's multi-brand portfolio and international reach across more than 100 markets suggests a well-established operation with diversified geographic revenue streams. The majority stake acquisition indicates Apheon's strategic interest in consolidating control of the business and its operations.
The transaction details—including the acquisition price, the percentage stake acquired, financing structure, and expected closing timeline—were not disclosed in available reporting.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.